



Original Article

Evaluation of anticancer activity of *Melaleuca Alternifolia* on Cervical cancer cell line (Hela) - an in-vitro study

Sujata M Byahatti^{1,*}, Chetana Bogar², Kishore Bhat³, Girish Dandagi⁴

¹ Professor, Department of Oral Medicine and Radiology, M M's N.G. Halgekar Institute of Dental Sciences and Research Centre, Belgaum, Karnataka, India, ² Research Officer, Central Research Laboratory, M M's N.G. Halgekar Institute of Dental Sciences and Research Centre, Belgaum, Karnataka, India, ³ Director, Department of Microbiology and Immunology, Central Research Laboratory, M M's N.G. Halgekar Institute of Dental Sciences and Research Centre, Belgaum, Karnataka, India, ⁴ Professor, Department of Pulmonary Medicine, Belgaum Institute of Medical Sciences, Belagavi, Karnataka, India.

ARTICLE INFO

ABSTRACT

Received:06 Aug 2018
Accepted:25 Aug 2018

Introduction and aims Cervical cancer has become the third most common cancer among women and second most common cause of death. The current treatment modality has issues of drug resistance and side effects. Hence, investigation of plant species as a source of experimental therapeutic agents, in treating cancer is currently gaining a lot of importance. One such naturally available plant extract is *Melaleuca alternifolia* (TTO) which belongs to the family of essential oils is a very good antibacterial, antifungal, antiviral, antiprotozoal and anti-inflammatory agent. But currently there is a lot of importance is given for its anticancer effect. Hence our aim is to evaluate anticancer activity of *Melaleuca alternifolia* on cervical cancer cell line (HeLa) by MTT assay an in vitro method. **Methodology:** Before the start of the study ethical clearance was obtained from Institutional Review Board. The cytotoxicity checked for cervical cancer (Hela) cell line and Vero Monkey kidney cell line which was used as a control in our current study. These cell lines were procured from NCCS Pune, India. 1. MTT solution preparation (stock solution): 5 mg in 1 ml of PBS. 2. Cell culture : The cell lines were maintained in 96 wells micro titer plate containing MEM media supplemented with 10% heat inactivated fetal calf serum (FCS), containing 5% of mixture of Gentamicin (10ug), Penicillin (100 Units/ ml) and Streptomycin (100µg/ml) in presence of 5% CO₂ at 37°C for 48-72 hours. 3. Cytotoxicity Assay: In vitro growth inhibition effect of test compound was assessed by calorimetric or spectrophotometric determination of conversion of MTT into Formazan blue by living cells. **Results** The results represent the mean of five readings. The IC₅₀ value of tea tree oil for cervical cancer cell line after 48 hrs was **3.125µg/ml**. Spearman's rho's Correlation showed P value <0.05 indicating there was statistical significant results obtained when TTO was treated with HeLa cervical cancer cell line for 48 hrs incubation period. **Conclusion:** TTO has a promising anticancer property against cervical cancer cell line (HeLa) with its IC₅₀ value **3.125µg/ml**. Hence this TTO with its greater efficacy related to its anticancer activity can be brought to the level of clinical trials in the coming future.

Keywords: Anticancer, Cytotoxicity, MTT assay, Tea tree oil.

1. INTRODUCTION

Breast and cervical cancers are the most common cancers in women worldwide. ¹ In India, cervical cancer is a leading cancer among women with annual incidence of about

Corresponding author *

Dr. Sujata.M.Byahatti

Associate Professor, Department of Oral medicine and Radiology, M M's N.G. Halgekar Institute of Dental sciences and research centre

E-mail: sujatabyahatti@rediffmail.com

1,30,000 cases and 70-75,000 deaths¹. India shares about one fourth of the global cervical cancer burden.²

Conventional medicine, surgery, chemotherapy and radiotherapy are primary approaches for cancer treatment, but they are not always effective. But, for many years, traditional medicines have been applied for the treatment of cancers in the world. Herbal medicines are generally low in cost, plentiful, and show very little toxicity or side effects in clinical practice.¹

One such naturally available plant extract derived from Australian native plant *Melaleuca alternifolia* i.e tea tree oil (TTO) , invented by Penfold³ in the year 1920 has many medicinal properties. Hence the aim of the current study was to evaluate the anticancer activity of one such naturally available plant extract *Melaleuca alternifolia*,i.e. Tea tree oil (TTO) against Cervical (HeLa) cancer cell line and Vero cell line by in vitro method MTT Assay.

2. MATERIAL AND METHODS

Source of data:

Before the start of the study ethical clearance was obtained by Institutional Review Board. We evaluated the anticancer activity of M.Alternifolia (i.e.TTO) on cervical cancer (Hela) and (Vero) Monkey kidney cell line which was used as control. The cell lines were procured from NCCS National Centre For Cell Science, Pune, India. Then subjected for MTT Assay to assess the cell viability and cell cytotoxicity (Cell Lysis). We received commercially available Tea tree oil from Crystal aromatics New Delhi, imported from Australia with Refractive index 1.475, at 25⁰ weight/ml was 0.8850gm/ml.

MTT Assay

1. MTT solution preparation (stock solution): 5 mg in 1 ml of PBS.

MTT (yellow dye) reduced by succinic dehydrogenase in the mitochondria of viable cells to purple formazan crystals. Formazan crystal production is directly proportional to the viable cells and inversely to the degree of cytotoxicity. When cells die, they lose the ability to convert MTT into formazan, thus color formation serves as a useful and convenient marker of only the viable cells.

2. Cell culture :

The cell lines were maintained in 96 wells micro titer plate containing MEM media supplemented with 10% heat inactivated fetal calf serum (FCS), containing 5% of mixture of Gentamicin (10ug), Penicillin (100 Units/ ml) and Streptomycin (100µg/ml) in presence of 5% CO₂ at 37°C for 48-72 hours.

3. Cytotoxicity Assay :

In vitro growth inhibition effect of test compound was assessed by calorimetric or spectrophotometric determination of conversion of MTT into “ Formazan blue” by living cells. Remove the supernatant from the plate and add fresh MEM solution and treat with different concentrations of extract or compound appropriately diluted

with DMSO. Control group contains only DMSO. In the current study, 10, 20, 25, 30 and 50ul of the stock solution (10mg / ml prepared in DMSO) were added to respective wells containing 100ul of the medium. So, the final concentrations were 10, 20, 25, 30 and 50ug / ml. That means to say the various concentration of TTO used to evaluate its anticancer activity were 100%, 50%, 25%, 12.5%,6.25%,3.125%, 1.562%, 0.781%, 0.390%, 0.195% respectively.

4. After 24hrs incubation at 37°C in a humidified atmosphere of 5% Co₂, stock solution of MTT was added to each well (20µl, 5mg per ml in sterile PBS) for further 4 hr incubation.

5. The supernatant carefully aspirated, the precipitated crystals of “Formazan blue” were solubilised by adding DMSO (100µl) and optical density was measured at wavelength of 570nm by using LISA plus.

6. The results represent the mean of five readings. The concentration at which the OD of treated cells was reduced by 50% with respect to the untreated control.

Formula :

Surviving cells (%) =

Mean OD of test compound / Mean OD at control × 100

Principle of assay:

This is a colorimetric assay that measures the reduction of yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase. The MTT enters the cells and passes into the mitochondria where it is reduced to an insoluble, coloured (dark purple) formazan product. The cells are then solubilised with an organic solvent (eg. DMSO, Isopropanol) and the released, solubilised formazan reagent is measured spectrophotometrically. Since reduction of MTT can only occur in metabolically active cells the level of activity is a measure of the viability of the cells.⁴

3. RESULTS

Table 1 shows the various concentrations of TTO, Mean OD noted for cervical cancer cell line with Cell viability and Cell Inhibition after incubation period of 48 hrs.

Table 1: The various concentrations of TTO, Mean OD noted for cervical (HeLa) cancer cell line with Cell viability and Cell Inhibition.

S.No.	Cell line	Concentration	Absorbance (nm)	% cell lysis	% of Cell Viability
1	Hela	100			
	48hrs				
2		50			
3		25	0.321	36.43%	63.57%
4		12.5	0.340	38.59%	61.41%
5		6.25	0.381	43.24%	56.76%
6		3.125	0.450	51.07%	48.93%
7		1.562	0.491	55.73%	44.27%
8		0.781	0.526	59.70%	41%
9		0.390	0.591	67.08	32.92%

10		0.195	0.681	77.29	22.71%
control		00	0.881		

Table 2 shows the various concentrations of TTO, Mean OD noted for Vero Monkey kidney cell line with Cell viability and Cell Inhibition after incubation period of 24 hrs.

Table 2: The various concentrations of TTO, Mean OD noted for (Vero) Monkey Kidney cell line with Cell viability and Cell Inhibition.

S.No.	Cell line	Concentration	Absorbance (nm)	% Cell Lysis	% Cell viability
1	Vero	100	0.473	3.3	96.63%
	(Control)		0.445		
2		50	0.475	97.78	2.21%
			0.454		
3		25	0.476	102.42	The proliferation of cells noted from this concentration
			0.497		
4		12.5	0.506	107.47	
			0.515		
5		6.25	0.523	109.57	
			0.518		
6		3.125	0.553	113.47	
			0.525		
7		1.562	0.580	118.42	
			0.545		
8		0.781	0.618	122.94	
			0.550		
9		0.390	0.686	130.94	
			0.559		
10		0.195	1.149	184.10	
			0.600		
control		00	0.482	0.475	
		00	0.469		

Table 3 shows Spearman's rho's Correlation with P value <0.050 indicating statistical significant results when TTO was treated with Cervical (HeLa) cancer cell line and Vero cell line.

Table 3: Spearman's rho Correlation Coefficient Correlation with TTO.

Hela Cell Line	SPEARMAN'S CORRELATION COEFFICIENT	P VALUE	SIGNIFICANT
Concentration Vs Cell Viability	-1.000	<0.050	Significant
Concentration Vs Cell Inhibition	+1.000	<0.001	Significant

Fig 1 shows TTO treated with cervical (Hela) cancer Cell line after 48h showing cytotoxic effect with 50% cell lysis.



Fig 1: The Photograph showing TTO treated with cervical (Hela) cancer Cell line after 48h showing cytotoxic effect with 50% cell lysis.






Fig 2: The Photograph showing TTO treated with VERO (Normal Monkey Kidney) Cell line after 24h showing no cell lysis.



Graph 1: Scatter plot showing TTO concentration, Cell death and viability for cervical (Hela) cancer cell line.

*IC₅₀ Value of TTO for Cervical (Hela) Ca cell line after 48hrs is 3.125µg/ml.



Graph 2: Scatter plot showing TTO concentration, Cell death and viability for Monkey kidney (vero) cell line.

*At higher concentration of Tea tree oil 2-4 cells death were noted. As the concentration reduced to 50% in Serial dilution the excessive proliferation of cells noted. This indicates that higher concentration of TTO had minimal cytotoxic effect, so lower concentration can be used for anticancer activity.

4. DISCUSSION

Currently, a great deal of research is focusing on the investigation of certain plant species as a source of experimental therapeutic agents. Although it has been known from the literature that more than 60% of anticancer agents which are currently in use are derived from natural resources⁵, but the toxic side effects generated and resistance to these and other synthetic drugs makes it necessary for the search of new novel agents.⁵

In our study we evaluated the anticancer activity of Tea tree oil by using in vitro method MTT assay. The cytotoxic effect was checked for HeLa and Vero cell lines after 48hrs and 24hrs respectively. IC₅₀ Value of TTO for Cervical (Hela) Ca cell line after 48hrs obtained was 3.125µg/ml (Table 1, Graph 1 and Fig 1). This indicates that higher concentration of TTO had great cytotoxic effect, so lower concentration can be sufficient to be used for anticancer activity. TTO had minimal cytotoxic effect on Vero cell line which was used as a control in our study than HeLa cell line. For Vero cell line, TTO at higher concentration showed 2-4 cells death. As the concentration reduced to 50% in Serial dilution there was excessive proliferation of cells noted (Table 2, Fig 2 and Graph 2). Spearman's rho's Correlation has shown statistical significant results when TTO was treated with Cervical (HeLa) cancer cell line and Vero cell line with P value <0.050 (Table 3).

Tea tree oil (TTO) which is an Australian native plant derivative belongs to the family of Myrtaceae is an essential oil which is obtained through steam distillation process from *Melaleuca alternifolia*,⁶ TTO has more than 100

components present in it, with terpinen-4-ol, γ -terpinene, α -terpinene, 1,8-cineole, and ρ -cymene are predominant. Terpinen-4-ol, being the most abundant and active component of the oil, which is responsible for the several *in vitro* and *in vivo* results reported for TTO^{7,8}. TTO has a wide range of mechanism of actions and it's a very good antibacterial^{9,10}, antifungal¹¹, antiviral¹², and anti-inflammatory agent¹³, currently lot of importance has been given for its anticancer activity¹⁴⁻¹⁶. The cytotoxicity of the TTO was tested on a wide panel of human cell cultures which includes cervical cancer (HeLa), acute lymphoblastic leukemia (MOLT-4), erythromyeloblastoid leukemia (K562), B cell derived from bone marrow of a patient with acute myeloid leukaemia (CTVR-1), fibroblast, and epithelial cells. The results of these studies showed an IC₅₀ value of TTO on cell growth ranging from 20 to 2700 µg/mL^{12,15,17,18}.

The most potential anticancer activity of TTO was initially reported in a study conducted by Calcabrini and colleagues (2004)¹⁹ in human melanoma M14 wild type cells and their drug-resistant counterparts, M14 adriamycin-resistant (ADR) cells.

TTO, at the higher concentrations (0.02 and 0.03%), as well as terpinen-4-ol, was able to inhibit the growth and induce caspase-dependent apoptotic cell death in both wild type and drug-resistant melanoma cells with the latter being more susceptible to the cytotoxic effect¹⁶.

The earlier studies also confirm the cytotoxic effect of TTO on murine mesothelioma (AE17) and melanoma (B16) which was higher than "normal" epithelial and fibroblast cells,²⁰. IC₅₀ values obtained were slightly different, which is probably due to the different cell types²¹.

TTO and terpinen-4-ol might elicit its effect by inhibiting rapidly dividing cells more readily than that of slower growing noncancerous cells²¹. More recently, the ability of TTO and its major component, terpinen-4-ol, has been also reported to interfere with the migration and invasion processes of drug-sensitive and drug-resistant melanoma cells¹⁴. Two recent studies investigated the efficacy of topical TTO on aggressive, subcutaneous, chemoresistant tumors in fully immune-competent mice^{22,23}. A follow-up study investigated the mechanism of action of TTO reporting that topically applied 10% TTO induced a direct cytotoxicity on subcutaneous AE17 tumor cells²³. However, *in vivo* findings were similar to previously suggested *in vitro* results^{16,22}.

Hence, terpinen-4-ol that is the likely to be the great mediator of an *in vitro* and *in vivo* efficacy of TTO²⁴. Only one study has demonstrated *in vitro* anticancer efficacy of 1,8-cineole against two human leukaemia cells lines through apoptosis²⁵.

IC₅₀ values of TTO reported for human cancer cell lines, HepG2 and HeLa were 0.002%-0.27% respectively²⁶ which was highly variable, depending on the type of cell examined. The observation that concentrations of 0.02% and 0.03% of

TTO which significantly reduce viability of M14 human melanoma cells after 48h¹⁹ supports our present data.

Hence, anticancer activity tea tree against various cell lines has shown better results in each experimental study which provokes the thought that the cytotoxic effect was predominant on the excessive proliferating cells than normal cells. So further work need to be performed to the level of animal studies then human trials in the coming future.

5. CONCLUSION

Efficacies of TTO as an anticancer agent with its IC₅₀ Value obtained from other studies were different and varying. This depends on the type of plant extract used, its concentration and method used. Hence, this IC₅₀ value of TTO with its greater efficacy related to its anticancer activity can be brought to the level of clinical trials in the coming future.

6. ACKNOWLEDGEMENTS

I would like to thank Rajiv Gandhi University of health sciences for providing grant for conducting the above research. I am thankful to our beloved principal Dr. Ramakant Nayak and Head of the department of Oral Medicine and radiology for support and encouragement

7. REFERENCES

1. Sakinehsalehi et al. Cytotoxic effect of Prangos Pabularia extract on HELA cell line a medicinal plant Int J Med Res Health Sci. 2016;5(11):547-552.
2. National cancer registry project (NCRP) Biennial report 2001, Indian Council of Medical Research, New Delhi.
3. Carson CF, Hammer KA, Riley TV *Melaleuca alternifolia* (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 2006; 19:50-62.
4. Alan Dolly and J. Brayen Griffiths. John Willey and Son's editors. Textbook of 'Cell And Tissue Culture For Medical Research'. John Wiley and sons publishers, page 62-64.
5. Newman, D.J., Cragg, G.M. and Snader, K.M. "Natural products as sources of new drugs over the period 1981-2002", J Nat Prod, 2003; 66: 1022-1037.
6. Hammer KA, Carson CF, Riley TV, Nielsen JB. A review of the toxicity of *Melaleuca alternifolia* (tea tree) oil. Food and chemical toxicology. 2006;44(5):616-25.
7. Brophy JJ, Craig DC, Goldsack RJ, Fookes CJ, Leach DN, Waterman PG. Triumthalone, a diketone from the volatile oil of the leaves of *Melaleuca triumphalis*, and its spontaneous conversion into isotriumthalone. Phytochemistry. 2006;67(18):2085-9.
8. F.Mondello, F. de Bernardis, A. Girolamo, A. Cassone, and G.Salvatore, "In vivo activity of terpinen-4-ol, the main bioactive component of *Melaleuca alternifolia* Cheel (tea tree) oil against azole-susceptible and -

resistant human pathogenic *Candida* species," BMC Infectious Diseases. 2006; 6:158.

9. Carson CF, Hammer KA, Riley TV. *Melaleuca alternifolia* (tea tree) oil: a review of antimicrobial and other medicinal properties. Clinical microbiology reviews. 2006;19(1):50-62.
10. Carson CF, Mee BJ, Riley TV. Mechanism of action of *Melaleuca alternifolia* (tea tree) oil on *Staphylococcus aureus* determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrobial agents and chemotherapy. 2002;46(6):1914-20.
11. Hammer K A, Carson C F, Riley T V. Antifungal activity of the components of *Melaleuca alternifolia* (tea tree) oil. Journal of Applied Microbiology 2003; 95(4):853-860.
12. Schnitzler P, Schon K, and Reichling J. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. Pharmazie, 2001; 56 (4):343-347.
13. P. H. Hart, C. Brand, C. F. Carson, T. V. Riley, R. H. Prager, and J. J. Finlay-Jones, "Terpinen-4-ol, the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by activated human monocytes," Inflammation Research, 2000; 49 (11):619-626.
14. Bozzuto G, Colone M, Toccaceli L, Stringaro A, Molinari A. Tea tree oil might combat melanoma. Planta medica. 2011;77(01):54-6.
15. Hayes AJ, Leach DN, Markham JL, Markovic B. In vitro cytotoxicity of Australian tea tree oil using human cell lines. Journal of Essential Oil Research. 1997;9(5):575-82.
16. A. Calcabrini, A. Stringaro, L. Toccaceli et al., Terpinen-4-ol, the main component of *Melaleuca alternifolia* (tea tree) oil inhibits the in vitro growth of human melanoma cells," Journal of Investigative Dermatology.2004;122(2):349-360..
17. T. A. Soderberg, A. Johansson, and R. Gref, "Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells," Toxicology, 1996;107(2): 99-109.
18. Mikus J, Harkenthal M, Steverding D, Reichling J. In vitro effect of essential oils and isolated mono- and sesquiterpenes on *Leishmania major* and *Trypanosoma brucei*. Planta Medica. 2000; 66(04):366-8.
19. Calcabrini, A., Stringaro, A., Toccaceli, L., Meschini, S., Marra, M., Colone, M., Salvatore, G., Mondello, F., Arancia, G. and Molinari, A. "Terpinen-4-ol, the main component of *Melaleuca alternifolia* (tea tree) oil inhibits the in vitro growth of human melanoma cells.[see comment]", Journal of Investigative Dermatology, 2004;122:349-360.
20. Teepe RG, Koebrugge EJ, Löwik CW, Petit PL, Bosboom RW, Twiss IM, Boxma H, Vermeer BJ, Ponc M. Cytotoxic effects of topical antimicrobial and

- Int J Pharma Res Health Sci. 2018; 6 (4). S2744-49
- antiseptic agents on human keratinocytes in vitro. The Journal of trauma. 1993;35(1):8-19.
21. Greay SJ, Ireland DJ, Kissick HT, Levy A, Beilharz MW, Riley TV, Carson CF. Induction of necrosis and cell cycle arrest in murine cancer cell lines by *Melaleuca alternifolia* (tea tree) oil and terpinen-4-ol. *Cancer Chemotherapy and Pharmacology*. 2010;65(5):877-88.
 22. Greay SJ, Ireland DJ, Kissick HT, Heenan PJ, Carson CF, Riley TV, Beilharz MW. Inhibition of established subcutaneous murine tumour growth with topical *Melaleuca alternifolia* (tea tree) oil. *Cancer chemotherapy and pharmacology*. 2010; 66(6):1095-102.
 23. Ireland DJ, Greay SJ, Hooper CM, Kissick HT, Filion P, Riley TV, Beilharz MW. Topically applied *Melaleuca alternifolia* (tea tree) oil causes direct anti-cancer cytotoxicity in subcutaneous tumour bearing mice. *Journal of Dermatological Science*. 2012 Aug 1;67(2):120-9.
 24. Mondello, F., De Bernardis, F., Girolamo, A., Cassone, A. and Salvatore, G."In vivo activity of terpinen-4-ol, the main bioactive component of *Melaleuca alternifolia* Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic *Candida* species", *BMC Infect Dis*,2006; 6:158.
 25. Moteki HI, Hibasami HI, Yamada YA, Katsuzaki HI, Imai KU, Komiya TA. Specific induction of apoptosis by 1, 8-cineole in two human leukemia cell lines, but not a in human stomach cancer cell line. *Oncology reports*. 2002; 9(4):757-60.
 26. Hayes AJ, Leach DN, Markham JL, Markovic B. In vitro cytotoxicity of Australian tea tree oil using human cell lines. *Journal of Essential Oil Research*. 1997; 9(5):575-82.

Conflict of Interest: None

Source of Funding: Nil